March 13, 2026 USA
In her column, Helena Strigård highlights Diamyd Medical as an example of a company preparing for global partnering. CEO Ulf Hannelius, CFO Niklas Axelsson and board member Dr. Karin Rosén discussed the company’s development of a disease-modifying treatment for type 1 diabetes based on antigen-specific immunotherapy and the importance of understanding the U.S. diabetes care ecosystem as the company approaches a pre-readout of its Phase 3 study. Read the article here
|
March 11, 2026 Sweden
Diamyd Medical presenterade bolaget under DNB Carnegies Healthcare Digital Micro Cap Seminarium den 9 mars 2026. Eventet samlade investerare och bolag inom hälso- och life science-sektorn och arrangerades i ett digitalt format.
Under presentationen intervjuades vd Ulf Hannelius av analytiker Maria Karlsson Osipova från DNB Carnegie. Samtalet berörde bland annat bolagets utveckling inom typ 1-diabetes, den pågående fas 3-studien DIAGNODE-3 samt den väntade interimsavläsningen av studiedata under mars 2026.
|
March 6, 2026 USA
In the latest episode of the Swedish American Chamber of Commerce in New England (SACC-NE) podcast, the discussion explores Nordic life science innovation in the U.S., featuring Swedish biotechnology company Diamyd Medical and its work to develop an immunotherapy aimed at preserving the body’s own insulin production in type 1 diabetes. Guest Dr. Karin Rosén, physician-scientist, SACC member, and Diamyd Medical board member, shares insights from her experience in global biopharma. The conversation is moderated by strategic communications executive Julie Ames in collaboration with Ventures Accelerated. Listen to the podcast here
|
March 6, 2026 Sweden
Diamyd Medical presenterade bolaget under Life Science-dagen den 4 mars 2026 i Wallenbergsalen vid Sahlgrenska Universitetssjukhuset i Göteborg. Eventet samlade investerare och bolag inom life science-sektorn och arrangerades av Företagsfinansiering Fyrstad AB och Nyhetsbyrån Finwire.
Under presentationen gav vd Ulf Hannelius en uppdatering om bolagets arbete inom typ 1-diabetes och utvecklingen av immunterapier som syftar till att bevara kroppens egen insulinproduktion.
|
March 6, 2026 Sweden
In a studio interview published by BioStock, Diamyd Medical CEO Ulf Hannelius, board member Professor Mark Atkinson, and Senior Director Joshua Vieth from the patient organisation Breakthrough T1D, discuss the current status of Diamyd Medical ahead of the upcoming march interim analysis of the pivotal Phase 3 DIAGNODE-3 trial. The discussion highlights the company’s antigen-specific immunotherapy being evaluated to preserve patients’ own insulin production in type 1 diabetes, as well as the clinical importance of maintaining endogenous insulin production for improved glucose control and long-term health outcomes. Watch the full discussion here
|